ANI Pharmaceuticals Ownership
| ANIP Stock | USD 59.39 1.53 2.64% |
Shares in Circulation | First Issued 1999-06-30 | Previous Quarter 19.3 M | Current Value 19.4 M | Avarage Shares Outstanding 6.5 M | Quarterly Volatility 6.4 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
ANI |
ANI Stock Ownership Analysis
About 100.0% of the company shares are held by institutions such as insurance companies. The book value of ANI Pharmaceuticals was presently reported as 20.74. The company has Price/Earnings To Growth (PEG) ratio of 1.06. ANI Pharmaceuticals recorded a loss per share of 0.47. The entity had not issued any dividends in recent years. The firm had 1:6 split on the 18th of July 2013. ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota. ANI Pharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 601 people. For more info on ANI Pharmaceuticals please contact Nikhil Lalwani at 218 634 3500 or go to https://www.anipharmaceuticals.com.Besides selling stocks to institutional investors, ANI Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different ANI Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align ANI Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
ANI Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
ANI Pharmaceuticals Insider Trades History
About 11.0% of ANI Pharmaceuticals are currently held by insiders. Unlike ANI Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against ANI Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of ANI Pharmaceuticals' insider trades
ANI Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as ANI Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading ANI Pharmaceuticals backward and forwards among themselves. ANI Pharmaceuticals' institutional investor refers to the entity that pools money to purchase ANI Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Tang Capital Management Llc | 2024-09-30 | 450 K | Geode Capital Management, Llc | 2024-09-30 | 425.2 K | Macquarie Group Ltd | 2024-06-30 | 388.1 K | Nuveen Asset Management, Llc | 2024-06-30 | 319.1 K | Amvescap Plc. | 2024-06-30 | 311.1 K | Charles Schwab Investment Management Inc | 2024-09-30 | 250.3 K | Renaissance Technologies Corp | 2024-09-30 | 245.1 K | Ameriprise Financial Inc | 2024-06-30 | 233.4 K | Thompson, Siegel & Walmsley Llc | 2024-09-30 | 230.2 K | Blackrock Inc | 2024-06-30 | 2.7 M | Vanguard Group Inc | 2024-09-30 | 1.3 M |
ANI Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ANI Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on ANI Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ANI Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
ANI Pharmaceuticals Outstanding Bonds
ANI Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. ANI Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most ANI bonds can be classified according to their maturity, which is the date when ANI Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| ANZNZ 345 21 JAN 28 Corp BondUS00182EBJ73 | View | |
| ANZNZ 345 17 JUL 27 Corp BondUS00182EBF51 | View | |
| Dana 575 percent Corp BondUS235822AB96 | View | |
| ANZNZ 2166 18 FEB 25 Corp BondUS00182EBP34 | View | |
| ANZNZ 5175122 18 FEB 25 Corp BondUS00182EBQ17 | View | |
| ANZNZ 125 22 JUN 26 Corp BondUS00182EBN85 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| AOL TIME WARNER Corp BondUS00184AAC99 | View |
ANI Pharmaceuticals Corporate Filings
F4 | 27th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 20th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 13th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
| 12th of July 2024 Other Reports | ViewVerify |
Pair Trading with ANI Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ANI Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ANI Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to ANI Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ANI Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ANI Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ANI Pharmaceuticals to buy it.
The correlation of ANI Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ANI Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ANI Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ANI Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for ANI Stock Analysis
When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.